Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, +23

Nature Communications

Mechanisms and therapeutic implications of hypermutation in gliomas

Mehdi Touat, Yvonne Y. Li, Adam N. Boynton, +75

Nature

Neuro-oncologyMedicineTherapeutic ImplicationsHigh-grade GliomasCell Biology +3

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, +30

Cancer Research

Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

Srivatsan Raghavan, Peter Winter, Andrew W. Navia, +44

Cell

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi, +35

JAMA Oncology

LKB1 loss links serine metabolism to DNA methylation and tumorigenesis

Filippos Kottakis, Brandon Nicolay, Ahlima Roumane, +16

Nature

ChromatinEpigenetic ChangeGeneticsEpigenomicsTumor Suppressor +5

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi, +29

Journal of Thoracic Oncology

Tumor BiologyProgrammed Death-MedicineCell DeathBronchial Neoplasm +8

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations

Yvonne Y. Li, Grace Tin‐Yun Chung, Vivian Wai Yan Lui, +36

Nature Communications

Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

Yvonne Y. Li, Glenn J. Hanna, Alvaro C. Laga, +3

Clinical Cancer Research

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Gonzalo Recondo, Magda Bahcall, Liam F. Spurr, +20

Clinical Cancer Research